热门资讯> 正文
FDA在设备应用中更容易利用现实世界的证据
2025-12-16 05:13
- The US FDA will no longer require that identifiable individual patient data be required from applicants when submitting real-world evidence as part of certain medical device applications.
- Sponsors have been clamoring for the change for some time as the individual patient data requirement was seen as burdensome and unnecessary.
- The agency said the move means that "meaningful information can be extracted from some big data sources without private, individual information."
- Since 2016, the FDA said more than 250 premarket authorizations for medical devices included real-world evidence.
- The agency added it is considering the same change for drugs and biologics applications.
More on Boston Scientific, Medtronic
- Medtronic: This Dividend Aristocrat Is Just Getting Started
- Boston Scientific Corporation (BSX) Presents at Citi Annual Global Healthcare Conference 2025 Prepared Remarks Transcript
- Medtronic plc (MDT) Q2 2026 Earnings Call Transcript
- Insider trades: Coca-Cola, Ford among notable names this week
- Notable analyst calls this week: Dell, Medtronic and T-Mobile among top picks
风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。